Navigation Links
Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma
Date:9/30/2009

JERUSALEM, Israel, September 30 /PRNewswire/ -- Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy. It is now available for online review at (http://informahealthcare.com/doi/abs/10.1517/14712590903321447).

Dr. Chan is the director of the Hematology/Oncology and Blood and Marrow Stem Cell Transplant Programs at the Texas Transplant Institute on the campus of Methodist Children's Hospital in San Antonio, Texas. He is also a principal investigator of the ExCell study currently evaluating StemEx. Dr. Petropoulos is a pediatric hematologist-oncologist at the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston, Texas, where the Phase I study of StemEx was conducted.

In the article Dr. Chan and Dr. Petropoulos note, "Early results suggested that carlecortemcel-l infusion ... may be associated with favorable non-relapse mortality rates ... ex vivo expansion of umbilical cord blood (UCB) cells appears to be a logical approach to increase the availability of this source for hematopoietic stem cell (HSC) transplantation. Laboratory research showed that the critical element of success is to improve HSC proliferation without promoting differentiation. The manufacturing of carlecortemcel-l represents a novel methodology that fulfills this criterion. It is the only product that has reached the confirmatory stage of clinical development. A single institution study (Phase I study at M. D. Anderson Cancer Center) suggested that the infusion of these expanded cells ... may improve transplant outcome in large-sized patients."

StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV along with the remaining unit of non-manipulated cells. It is currently being evaluated in an international, Phase II/III, FDA, pivotal registration study called ExCell, now enrolling adolescents and adults with high-risk hematologic malignancies, at clinical sites in the U.S., Italy, Spain, Hungary and Israel. (http://www.stemexstudy.com ).

The study is being conducted to verify the safety and efficacy of this product by comparing the overall 100-day mortality with that of a historical cohort from international umbilical cord

blood transplant registries. It is also evaluating the feasibility of centralized manufacturing and shipping of expanded cord blood cells to transplant centers for infusion. The speed and completeness of engraftment and the long-term hematologic and immunologic reconstitution of the recipients will shed light on the role of expanded UCB cells in transplantation.

StemEx is being developed by the joint venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: Teva). Market launch is anticipated for 2011.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com. For information regarding the ExCell study: http:http://www.stemexstudy.com.

    Press contact:
    Marjie Hadad
    Media Liaison/IR
    Gamida Cell
    marjie@gamida-cell.com
    +972-54-536-5220


SOURCE Gamida Cell LTD


'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. ACRO Comments on NEJM Article on Globalization of Clinical Research
4. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
5. InVitrias Cellastim Showcased in Nature Article
6. Particle Sciences Expands Its Combination Product Capabilities
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
9. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
10. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 ... new market research report "Pharmaceutical Packaging Equipment Market by ... Labeling & Serialization), by Product Type (Tablet, Powder, Cream, ... published by MarketsandMarkets, studies the global market during the forecast ... to grow at a CAGR of 6.9% during the ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... , February 10, 2016 ... Medicine, Targeted Therapeutics and Companion Diagnostic Market to ... Participants, and Environment" research report indicates that the ... $149 billion by 2020 growing at a CAGR ... companion diagnostics and targeted therapeutics and is dominated ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):